惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

D
Docker
阮一峰的网络日志
阮一峰的网络日志
T
Tailwind CSS Blog
博客园 - 【当耐特】
量子位
博客园 - 叶小钗
有赞技术团队
有赞技术团队
Jina AI
Jina AI
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
博客园 - Franky
博客园 - 司徒正美
爱范儿
爱范儿
美团技术团队
小众软件
小众软件
酷 壳 – CoolShell
酷 壳 – CoolShell
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
V
V2EX
罗磊的独立博客
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
Last Week in AI
Last Week in AI
Hugging Face - Blog
Hugging Face - Blog
I
InfoQ
D
DataBreaches.Net
宝玉的分享
宝玉的分享

Hacker News: Best

madhadron - The seven programming ur-languages GitHub - smol-machines/smolvm: Tool to build & run portable, lightweight, self-contained virtual machines. I Measured Claude 4.7's New Tokenizer. Here's What It Costs You. Introducing Claude Design by Anthropic Labs It Is Time to Ban the Sale of Precise Geolocation The creative software industry has declared war on Adobe Isaac Asimov: The Last Question Newly unsealed records reveal Amazon’s price-fixing tactics, California attorney general claims Clojure - Documentary Android CLI and skills: Build Android apps 3x faster using any agent Qwen3.6-35B-A3B on my laptop drew me a better pelican than Claude Opus 4.7 Codex:全能型助手 Introducing Claude Opus 4.7 Qwen Studio The Future of Everything is Lies, I Guess: Where Do We Go From Here? Virginia Bans Sale of Geolocation Data YouTube now lets you turn off Shorts Burgers | マクドナルド公式 ChatGPT for Excel Ask HN: Who is using OpenClaw? Live Nation illegally monopolized ticketing market, jury finds Google Broke Its Promise to Me. Now ICE Has My Data. Open Source Isn't Dead. The Future of Everything is Lies, I Guess: New Jobs Unexpected €54k billing spike in 13 hours: Firebase browser key without API restrictions used for Gemini requests IPv6 – Google Your Backpack Got Worse On Purpose Good sleep, good learning, good life Fixing a 20-year-old bug in Enlightenment E16. Does Gas Town 'steal' usage from users' LLM credits & paid services to improve itself?
What Ozempic Does to the Gut-Brain Axis
Scott C. Anderson · 2026-06-28 · via Hacker News: Best

“I’ve been taking Ozempic to lose weight but now I want to go hiking and play badminton with my friends.” —Bob Janke

Researchers rejoiced when Ozempic and other GLP-1 drugs worked to shed weight in their patients. But there was an unexpected bonus: Some depressed patients started to feel better. Researchers from Southeast University in China, led by Honghong Yao, think they know why. They pieced together several related observations to solve the mystery.

(I apologize in advance for a few gnarly bacterial names up ahead in this article. But the story is compelling, and you really don’t need to remember the names of the characters to appreciate the plot, so hang in there.)

GLP-1s and Your Gut: What's the Connection?

When GLP-1 drugs like Ozempic, Wegovy, and Trulicity are injected, they find their way to the gut. That’s not unexpected; GLP-1 drugs act on your gut to make you feel satiated. That’s where your body makes its own GLP-1, after all.

Yet one of the researchers’ most interesting findings is that people with major depressive disorder or anxiety tend to have significantly lower natural levels of GLP-1. That’s the first piece of the puzzle.

When tested on mice, GLP-1 drugs not only make them lose weight; they also reverse depression-like behavior. So, higher GLP-1 appears to act as an antidepressant, which fits well with the first puzzle piece. (Mice are not perfect proxies for people, but they are surprisingly useful when it comes to studies of depression and anxiety. Scientists are not supposed to anthropomorphize, but if you saw a mouse with “depression-like behavior,” you'd probably recognize it immediately. Still, mice are not humans, so keep that in mind.)

Every hormone the body releases has a receptor. That goes for GLP-1 as well. Its receptor is parsimoniously named GLP-1R. Interestingly, the researchers found that if they block GLP-1R, the mice don’t lose weight anymore—but they still reverse their depression. That means that whatever is causing the weight loss seems to be unrelated to the psychiatric change. That is a major plot twist, and a big puzzle piece.

Intriguingly, depression is not reversed in germ-free mice. Whatever GLP-1 is doing, it apparently has something to do with microbes. Without microbes, there is no antidepressant effect. The researchers then used genomic sequencing to see what impact the GLP-1 was having on the gut microbiome, and they discovered a significant enrichment of Lactobacillus delbrueckii. The final piece of the puzzle came in the shape of a microbe.

The researchers say, “We demonstrated that liraglutide [a related GLP-1 drug] directly promotes the growth of Lactobacillus delbrueckii.” They showed that liraglutide helped the bacterium to produce endocannabinoids, which act a little like cannabis to reduce the effects of stress on the amygdala and hypothalamus. In other words, GLP-1 helps gut microbes make home-grown mood-boosters.

Most of these amazing results are correlational. To seal the deal and show causality, the researchers transferred poop from the GLP-1 mice to other depressed mice. You and I might not rejoice at an offering of mouse poop, but mice are into it. Like a shocking number of other animals, mice are coprophagic, or poop-eaters. The depressed mice that received poop from the GLP-1 mice were significantly cheered up.

The same antidepressant effect was seen when they gave depressed mice a straight shot of L. delbrueckii. That makes L. delbrueckii a psychobiotic: a microbe that can improve mood. The most common subspecies of L. delbrueckii is L. bulgaricus. And now we can reveal how to get some of this good stuff yourself. Your best bet is with live ferments, like yogurt, kefir, and cheese. These may even help you lower your cholesterol and fight off cancer.

(It is, however, a pathogen in your urinary tract. Hey, it’s a microbe, not a superhero.)

Putting It All Together: GLP-1s and the Microbiome

This is not the first study to find that GLP-1 drugs affect the microbiome. A recent Polish study led by Sylwia Małgorzewicz found an increase in Akkermansia and Ruminococcus species in humans and mice. These microbes are associated with improvements in metabolism.

Interestingly, while all GLP-1 drugs had effects on the gut microbiome, each individual drug had a slightly different impact. Dulaglutide, for instance, seemed to have a better impact on the microbiome than semaglutide. Doctors might want to give patients a short psych eval before choosing the appropriate GLP-1 drug.

It may be hard to remember, but GLP-1 drugs were originally meant for people with type 2 diabetes. And here, too, there is a microbial angle. People with type 2 diabetes have altered gut microbes, with a reduction in Bifidobacterium, an important denizen of our gut when we were babies. This genus slowly dies off as we age (and stop drinking milk), but it fades faster in people with diabetes. Interestingly, people who incorporate more fiber in their diet not only increase beneficial microbes, they also increase their own production of GLP-1 and lower their obesity-induced insulin resistance.

That means that at least some of the effects of Ozempic can be found in a few scoops of yogurt. It’s tasty and a lot cheaper.

References

Bian, Liang, Yang Cai, Yuan Zhang, et al. “Microbiota-Driven Gut-Brain Signaling Underlies Antidepressant Effects of a GLP-1 Analog.” Cell Host & Microbe 34, no. 6 (2026): 1000-1017.e5.

Nami, Yousef, Anahita Barghi, Mahsa Sadeghi, Tara Farhadi, and Babak Haghshenas. “Lactobacillus Delbrueckii: A Functional Powerhouse in Dairy Fermentation and Emerging Probiotic Applications.” Food Science & Nutrition 14, no. 2 (2026): e71546.

Gofron, Krzysztof Ksawery, Andrzej Wasilewski, and Sylwia Małgorzewicz. “Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.” Nutrients 17, no. 8 (2025): 1303.

Zeng, Yuan, Yifan Wu, Qian Zhang, and Xinhua Xiao. “Crosstalk between Glucagon-like Peptide 1 and Gut Microbiota in Metabolic Diseases.” mBio 15, no. 1 (n.d.): e02032-23.